What Is Driving Senseonics (NASDAQ:SENS) Up 13% Pre-Market Following Its Q3 Results on Tuesday?

Vinay Lochav

10 November 2026 11:43 PM AEDT

What Is Driving Senseonics (NASDAQ:SENS) Up 13% Pre-Market Following Its Q3 Results on Tuesday?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Early trading placed Senseonics (NASDAQ:SENS) at USD 11.10 on Tuesday, November 10, 2026, a 13.27% lift on a calculated prior close of USD 9.80, equal to roughly USD 1.30 a share.
Q3 2026 results issued November 9, 2026 showed Revenue of USD 19.6 million, roughly 140% above USD 8.1 million, including USD 16.8 million from the US and a gross Margin close to 62%.
The 2026 full-year revenue outlook moved up to USD 68 million to USD 70 million, previously USD 62 million to USD 66 million, which points to 93% to 98% growth and a gross margin above 60%.
Net loss came in at USD 32.7 million (USD 0.50 a share), compared with USD 19.5 million twelve months earlier, while cash stood at USD 126.6 million versus USD 55.0 million in principal debt.

Pre-Market Price Action for Senseonics (+13.27%)

Senseonics, maker of the Eversense implantable glucose monitor, published its third-quarter 2026 numbers on November 9, 2026. Sales came to USD 19.6 million, about 140% higher than USD 8.1 million a year before. Domestic sales climbed roughly 160%, reaching USD 16.8 million from USD 6.4 million, while overseas sales increased about 65%, moving to USD 2.8 million from USD 1.7 million. Gross Profit reached USD 12.1 million, a margin close to 62% compared with 43% twelve months prior. On Tuesday, November 10, the pre-market quote was USD 11.10, a 13.27% rise, and a back-of-envelope calculation places the previous close around USD 9.80.

Why the Stock Reacted: Higher Forecasts and Rising Costs

The quarterly release is the identified trigger. Leadership lifted its 2026 revenue forecast to USD 68 million to USD 70 million, up from USD 62 million to USD 66 million, and nudged its gross margin view to above 60%, versus a previous 58% to 61%, while international revenue made up close to 15% of the total. Generally, higher forecasts prompt model updates and pre-market buying. Expenses also increased: selling, general and administrative costs reached USD 32.3 million compared with USD 15.3 million, and Research and Development spending rose to USD 11.7 million from USD 7.8 million. The net loss therefore widened to USD 32.7 million, or USD 0.50 a share, up from USD 19.5 million, or USD 0.43.

Valuation, Cash Position and Downside Risks for Senseonics

The filing listed 54,775,503 shares outstanding at September 30, 2026. At USD 11.10 that works out to a calculated Market Value of about USD 608 million, though the weighted-average figure of 65,736,278 does not tie out and needs checking. Cash, cash equivalents and short-term investments totalled USD 126.6 million, while the Hercules Facility carried USD 55.0 million in principal, booked at USD 56.2 million. With the company still loss-making, further share or Debt raisings could dilute existing holders. A 13.27% gain in thin pre-market trade with wide spreads could be erased at the 9:30 a.m. ET open, and the 52-week range and average Volume were not checked here.

Where Things Stand

Senseonics (NASDAQ:SENS) trades 13.27% higher at USD 11.10 before the regular session on November 10, 2026, following the November 9 report of Q3 revenue at USD 19.6 million, a gross margin close to 62% and a 2026 revenue outlook lifted to USD 68 million to USD 70 million. Offsetting these are the USD 32.7 million net loss, which widened, USD 55.0 million in debt and light pre-market liquidity.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.